Department of Urology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea.
Int J Hyperthermia. 2012;28(3):227-34. doi: 10.3109/02656736.2012.666319.
To compare percutaneous radiofrequency ablation (RFA) and open partial nephrectomy (OPN) for the treatment of renal cell carcinoma (RCC) with respect to renal function and mid-term oncological outcome.
From January 2006 to December 2008, 40 (RFA group) and 110 (OPN group) patients underwent RFA and OPN for sporadic RCC, respectively. The sizes and locations of RCCs were matched between the two groups. To determine the lesion size, the maximum transverse diameter was measured. Estimated glomerular filtration rates (eGFR) before and after treatment and overall three-year recurrence-free survival rates were calculated and compared.
Tumours in the RFA and OPN groups ranged from 9-76 mm (24.4 ± 13.1 mm) and from 6-60 mm (22.3 ± 10.2 mm), respectively (p = 0.962). The locations of RCCs were not significantly different (p = 0.101-0.508). The mean reductions of eGFR in the RFA and OPN groups were 2.3 ± 8.6 mL/min/1.73 m² (range, -23 to +17.5 mL/min/1.73 m²) and 7.4 ± 10.9 mL/min/1.73 m² (-23.6 to +42.8 mL/min/1.73 m², respectively (p = 0.013). Overall three-year recurrence-free survival rates in the RFA and OPN groups were 94.7% and 98.9%, respectively (p = 0.266).
For treating size- and location-matched RCCs, RFA is superior to OPN with respect to the preservation of renal function. Furthermore, RFA can achieve excellent mid-term outcomes that are equivalent to those of OPN.
比较经皮射频消融(RFA)和开放性部分肾切除术(OPN)治疗肾细胞癌(RCC)在肾功能和中期肿瘤学结果方面的差异。
2006 年 1 月至 2008 年 12 月,分别有 40 例(RFA 组)和 110 例(OPN 组)接受 RFA 和 OPN 治疗散发性 RCC。两组的 RCC 大小和位置相匹配。为了确定病变大小,测量了最大横径。计算并比较了治疗前后的估算肾小球滤过率(eGFR)和总 3 年无复发生存率。
RFA 和 OPN 组肿瘤大小分别为 9-76mm(24.4±13.1mm)和 6-60mm(22.3±10.2mm)(p=0.962)。RCC 的位置无显著差异(p=0.101-0.508)。RFA 和 OPN 组 eGFR 的平均降低值分别为 2.3±8.6mL/min/1.73m²(范围为-23 至+17.5mL/min/1.73m²)和 7.4±10.9mL/min/1.73m²(-23.6 至+42.8mL/min/1.73m²,p=0.013)。RFA 和 OPN 组的总 3 年无复发生存率分别为 94.7%和 98.9%(p=0.266)。
对于大小和位置相匹配的 RCC,RFA 在保护肾功能方面优于 OPN。此外,RFA 可以实现与 OPN 相当的优异中期结果。